The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs ...

Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared ...

The CHMP has put its stamp of approval on Boehringer Ingelheim’s Jascayd for two lung disorders—idiopathic pulmonary fibrosis ...

A year after a major layoff round at its Allergan headquarters in California, AbbVie is making more edits to its workforce with a new round of 85 layoffs.  | The layoffs at AbbVie's Irvine, California ...

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once ...

A web of mail-order pharmacies, wholesalers and patient services groups connected to the self-styled largest Pentecostal ...

Gilead Sciences and the World Health Organization (WHO) are doubling down on a pact to eliminate deadly parasitic disea | ...

AbbVie's 85 layoffs are tied to its Allergan Aesthetics headquarters in California, while Novartis is cutting more staff at ...

Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the ...

Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. Local know-how, proper due diligence and AI are helpful in striking ...

In the phase 3b study, 49% of those on Bimzelx achieved reduced disease activity versus 38% of those on Skyrizi at Week 16.